Sharp Therapeutics Corp. (Sharp Therapeutics), formerly EVP Capital Inc. (EVP Capital), an Ontario corporation is pleased to announce the successful completion of its qualifying transaction by way of a reverse takeover of Sharp Edge Labs, Inc. (Sharp Edge). Pursuant to a statutory plan of arrangement under the Business Corporations Act (Ontario), EVP Capital acquired all the issued and outstanding common stock in the capital of Sharp Edge in exchange for common shares of the resulting issuer, Sharp Therapeutics. Sharp Therapeutics will begin trading on the TSXV under the symbol "SHRX" in late December 2024.
Bennett Jones acted for Sharp Edge Labs, Inc.
The Bennett Jones team was led by Marshall Eidinger (Securities and M&A) and includes Dominique Carli, Geoff Davis, Tatiana Henkenhaf, Jonathan Berg (Securities and M&A), James Morand (Tax), Joseph Blinick and Will Bortolin (Litigation).
Read the transaction press release.